Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers

Background The dismal clinical outcome of relapsed/refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL) highlights the need for innovative targeted therapies. Although chimeric antigen receptor (CAR)-engineered T cells have revolutionized the treatment of B cell malignancies, their clinical...

Full description

Bibliographic Details
Main Authors: Pablo Menendez, Diego Sánchez Martínez, Néstor Tirado, Alba Martínez-Moreno, Anaïs Jiménez-Reinoso, Víctor M Díaz, Marina García-Peydró, Oana Hangiu, Laura Díez-Alonso, Ángela Albitre, Petronila Penela, Maria L Toribio, Luis Álvarez-Vallina
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/12/e005333.full

Internet

https://jitc.bmj.com/content/10/12/e005333.full

Similar Items